Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Presentation Date and Time: June 18, 2025, at 11:45 AM ET Location : ...

Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being ...

The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Tuesday, June 17, 2025 under the Company's existing trading symbol "SNSE" with the new CUSIP ...

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide further analysis from its recently completed Phase 3 COMPETE trial in an ...

“This isn’t just another token buy—it’s a strategic fetch,” said David Tobias, CEO of Dogecoin Cash, Inc. “DOGP now holds over two billion DOG tokens, giving us a significant footprint in the evolving ...

RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneer in advanced retinal imaging and precision medicine, is pleased to announce the appointment of Dr. Taimour Langaee ...

Cette équipe de l’Université de Vienne présente une avancée importante dans le diagnostic et du traitement des métastases cérébrales, avec cette publication, dans la revue Nature Medicine, des ...

Significant Symptom Reduction: Patients treated with Avextra's extract showed statistically and clinically significant improvement in MIDOS scores (a palliative symptom assessment tool), while the ...

The OTCID market tier, launched by OTC Markets in 2024, is specifically designed for established, international issuers that meet higher standards of disclosure and governance. OTCID-listed companies ...

“We are excited to announce this major milestone in our mission to bring breakthrough therapies to patients. This marks the next phase of development for our lead candidate, STAR-LLD, and represents a ...

(NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, ...